GERMANTOWN, Md. and GUANGZHOU, China, April 27, 2023 /PRNewswire/ — RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance from the United States Food & Drug Administration (FDA) cleared its Investigational…Read More
RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV1730 COVID19 Booster Vaccine MarketScreener
